AI Pharmaceuticals Jamaica

AI Pharmaceuticals Jamaica is a Jamaica-incorporated pharmaceutical and formulation R&D company focused on discovering and developing combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals derived from cannabinoids, psilocybin mushrooms, fungi, ayahuasca, and other medicinal plants. The company has positioned Jamaica as a legal R&D base for psychedelic- and cannabis-related work and has emphasized the use of artificial intelligence and data mining to identify potentially synergistic formulations. In 2020, the company was acquired indirectly when Osoyoos Cannabis, later renamed Aion Therapeutic, acquired its parent PCAI Pharma. In 2021, Aion sold certain related intellectual property to Apollon Formularies while continuing to leverage its Jamaica presence for psychedelic psychiatry operations. Public disclosures describe AI Pharmaceuticals Jamaica primarily as an early-stage discovery and IP-generating subsidiary rather than a clinical-stage developer with named human-stage drug candidates.